Integra Lifesciences IART
$13.25 −$0.30 (-2.21%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.99 -1.96%
Open$13.38
Prev close$13.55
Day range$13.16 – $13.79
Volume828.6K
Market cap$1.03B
P/E (TTM)77.9
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$411.18M+2.3% YoY
Operating profit$18.90M+60.7% YoY
Net profit$14.85M+374.8% YoY
Diluted EPS$0.19+371.4% YoY
Free cash flow$85.73M+232.9% YoY
Operating cash flow$95.98M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin52.4%
Operating margin4.4%
Net margin0.8%
Return on equity0.7%
Return on assets0.4%
Return on invested capital2.1%
Current ratio3.62
Liabilities / assets69.6%
Cash & investments$311.93M
Total debt$161.09M
Net cash (debt)$150.84M
Free cash flow / sales4.3%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $411.18M | $418.76M | $391.92M | $1.64B | $434.93M |
| Total Operating Revenue | $411.18M | $418.76M | $391.92M | $1.64B | $434.93M |
| Cost of Revenue | $201.32M | $199.02M | $174.94M | $803.63M | $214.06M |
| Gross Profit | $209.87M | $219.74M | $216.98M | $831.62M | $220.87M |
| Operating Expense | $190.97M | $200.46M | $205.51M | $813.63M | $197.83M |
| Selling and Admin Expenses | $165.31M | $172.44M | $178.24M | $699.70M | $169.27M |
| Research & Development | $21.90M | $24.25M | $23.50M | $98.97M | $24.79M |
| Depreciation & Amortization & Depletion | $3.76M | $3.77M | $3.78M | $14.95M | $3.77M |
| -Depreciation & Amortization | $3.76M | $3.77M | $3.78M | $14.95M | $3.77M |
| Operating Profit | $18.90M | $19.29M | $11.47M | $18.00M | $23.04M |
| Net Non-Operating Interest Income (Expense) | -$17.96M | -$18.73M | -$18.36M | -$67.78M | -$19.31M |
| Non-Operating Interest Income | $5.00M | $4.27M | $4.11M | $18.47M | $4.36M |
| Non-Operating Interest Expense | $22.96M | $22.99M | $22.47M | $86.26M | $23.67M |
| Other Income (Expense) | $14.72M | $4.19M | $4.48M | -$513.72M | $581,000.00 |
| Special Income (Charges) | $0.00 | $0.00 | – | -$511.37M | $0.00 |
| -Less:Impairment of Capital Assets | $0.00 | $0.00 | – | $511.37M | $0.00 |
| Other Non-Operating Income (Expenses) | $14.72M | $4.19M | $4.48M | -$2.35M | $581,000.00 |
| Pretax Profit | $15.66M | $4.74M | -$2.41M | -$563.50M | $4.31M |
| Tax | $812,000.00 | $262,000.00 | $2.21M | -$47.03M | $6.01M |
| Net Profit | $14.85M | $4.48M | -$4.62M | -$516.47M | -$1.70M |
| Profit from Continuing Operations | $14.85M | $4.48M | -$4.62M | -$516.47M | -$1.70M |
| Net Income to Parent Company | $14.85M | $4.48M | -$4.62M | -$516.47M | -$1.70M |
| Net Income to Common Stockholders | $14.85M | $4.48M | -$4.62M | -$516.47M | -$1.70M |
| Basic EPS | $0.19 | $0.06 | -$0.06 | -$6.74 | -$0.02 |
| Diluted EPS | $0.19 | $0.06 | -$0.06 | -$6.74 | -$0.02 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $3.51B | $3.56B | $3.58B | $3.60B | $3.60B |
| Total Current Assets | $1.19B | $1.19B | $1.17B | $1.16B | $1.16B |
| Cash and Cash Equivalents & Short-Term Investments | $311.93M | $274.08M | $265.50M | $263.74M | $263.74M |
| -Cash and Cash Equivalents | $252.26M | $214.42M | $236.81M | $235.05M | $235.05M |
| -Short Term Investments | $59.67M | $59.67M | $28.69M | $28.69M | $28.69M |
| Prepaid Assets | $117.62M | $104.34M | $97.71M | $96.09M | $96.09M |
| Other Current Assets | $1.07B | $53.86M | $49.35M | $28.13M | $28.13M |
| Total Non-Current Assets | $2.32B | $2.37B | $2.41B | $2.44B | $2.44B |
| -Goodwill | $607.83M | $611.15M | $613.25M | $615.16M | $615.16M |
| Non-Current Deferred Assets | $66.71M | $70.44M | $68.08M | $69.85M | $69.85M |
| Other Non-Current Assets | $2.25B | $31.59M | $34.96M | $37.88M | $37.88M |
| Total Liabilities | $2.44B | $2.52B | $2.54B | $2.56B | $2.56B |
| Total Current Liabilities | $329.00M | $330.88M | $346.85M | $455.98M | $455.98M |
| -Accounts Payable | $66.42M | $82.64M | $87.95M | $95.73M | $95.73M |
| Current Accrued Expenses | $101.84M | $107.62M | $133.32M | $130.49M | $130.49M |
| -Current Capital Lease Obligation | $14.59M | $13.92M | $13.93M | $14.02M | $14.02M |
| Total Non-Current Liabilities | $2.11B | $2.19B | $2.19B | $2.10B | $2.10B |
| Long Term Debt and Capital Lease Obligation | $161.09M | $1.99B | $1.99B | $1.89B | $1.89B |
| -Long Term Capital Lease Obligation | $161.09M | $162.66M | $160.12M | $163.06M | $163.06M |
| Other Non-Current Liabilities | $2.11B | $194.40M | $195.56M | $204.28M | $204.28M |
| Total Equity | $1.07B | $1.04B | $1.04B | $1.04B | $1.04B |
| Stockholders' Equity | $2.47B | $1.04B | $1.04B | $1.04B | $1.04B |
| Capital Stock | $0.00 | $921,000.00 | $922,000.00 | $923,000.00 | $923,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.35B | $1.35B | $1.34B | $1.34B | $1.34B |
| Retained Earnings | $438.16M | $423.31M | $418.82M | $423.44M | $423.44M |
| Less: Treasury Stock | -$684.09M | -$686.92M | -$687.12M | -$689.21M | -$689.21M |
| Receivables | – | $267.19M | $264.41M | $278.85M | $278.85M |
| -Accounts Receivable | – | $267.19M | $264.41M | $278.85M | $278.85M |
| Inventory | – | $492.01M | $495.04M | $492.74M | $492.74M |
| Net PPE | – | $583.29M | $584.08M | $584.90M | $584.90M |
| -Gross PPE | – | $583.29M | $584.08M | $1.03B | $1.03B |
| Goodwill and Other Intangible Assets | – | $1.69B | $1.72B | $1.75B | $1.75B |
| -Other Intangible Assets | – | $1.08B | $1.11B | $1.13B | $1.13B |
| Payables | – | $85.87M | $91.18M | $99.38M | $99.38M |
| -Total Tax Payable | – | $3.24M | $3.24M | $3.65M | $3.65M |
| Short-Term Debt and Capital Lease Obligation | – | $57.51M | $52.68M | $140.57M | $140.57M |
| -Current Debt | – | $43.59M | $38.75M | $126.55M | $126.55M |
| Current Deferred Liabilities | – | $11.70M | $11.62M | $11.46M | $11.46M |
| -Long Term Debt | – | $1.83B | $1.83B | $1.73B | $1.73B |
| Non-Current Deferred Liabilities | – | $3.47M | $6.14M | $5.66M | $5.66M |
| -Common Stock | – | $921,000.00 | $922,000.00 | $923,000.00 | $923,000.00 |
| Gains/Losses Not Affecting Retained Earnings | – | -$40.20M | -$30.94M | -$30.08M | -$30.08M |
| -Accumulated Depreciation | – | – | – | -$443.95M | -$443.95M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $95.98M | $22.80M | $9.80M | $50.38M | $11.82M |
| Net cash flow from continuing operations | $95.98M | $22.80M | $9.80M | $50.38M | $11.82M |
| Net Income from Continuing Operations | $14.85M | $4.48M | -$4.62M | -$516.47M | -$1.70M |
| Gain/Loss from Continuing Operations | $1.48M | $643,000.00 | $90,000.00 | $490,000.00 | $0.00 |
| Depreciation & Depletion & Amortization | $39.06M | $38.14M | $38.43M | $151.83M | $38.43M |
| Deferred Tax | $703,000.00 | -$4.33M | $1.33M | -$66.26M | -$10.95M |
| Other Non-Cash Items | -$206,000.00 | $4.16M | $32,000.00 | -$15.41M | -$4.45M |
| Change in Working Capital | $37.19M | -$26.13M | -$30.62M | -$33.74M | -$15.35M |
| -Change in Receivables | $17.96M | -$3.04M | $13.65M | -$485,000.00 | -$16.45M |
| -Change in Inventory | $24.13M | $474,000.00 | -$4.33M | -$46.76M | -$3.34M |
| -Change in Prepaid Assets | -$1.33M | -$7.44M | -$21.88M | -$2.80M | $2.19M |
| -Change in Payables and Accrued Expense | -$4.15M | -$15.20M | -$19.19M | $26.72M | $23.02M |
| -Change in Other Current Assets | $1.83M | -$996,000.00 | $1.39M | $3.34M | $8,000.00 |
| -Change in Other Current Liabilities | -$1.03M | $836,000.00 | $369,000.00 | -$17.16M | -$21.46M |
| -Change In Other Working Capital | -$228,000.00 | -$762,000.00 | -$630,000.00 | $3.40M | $685,000.00 |
| Net cash flow from investing | -$10.25M | -$43.28M | -$14.85M | -$108.06M | -$34.91M |
| Net Cash Flow from Continuing Investing Activities | -$10.25M | -$43.28M | -$14.85M | -$108.06M | -$34.91M |
| Net PPE Purchase and Sale | -$10.25M | -$12.31M | -$14.85M | -$81.44M | -$17.21M |
| Net Investment Purchase and Sale | $0.00 | -$30.98M | $0.00 | -$12.43M | -$3.49M |
| Financing Cash Flow | -$46.29M | -$818,000.00 | $8.30M | $28.34M | $24.34M |
| Net Cash Flow from Continuing Financing Activities | -$46.29M | -$818,000.00 | $8.30M | $28.34M | $24.34M |
| Net Issuance Payments Of Debt | -$46.09M | $6.51M | $8.91M | $50.81M | $24.61M |
| Net Common Stock Issuance | $0.00 | – | – | -$221,000.00 | $0.00 |
| Proceeds from Stock Option Exercised | $0.00 | $0.00 | $760,000.00 | $957,000.00 | $0.00 |
| Net Other Financing Charges | -$200,000.00 | -$7.33M | -$1.38M | -$23.21M | -$271,000.00 |
| Ending Cash Balance | $252.26M | $214.42M | $236.81M | $235.05M | $235.05M |
| Net Change in Cash | $39.44M | -$21.30M | $3.25M | -$29.34M | $1.25M |
| Beginning Cash Balance | $214.42M | $236.81M | $235.05M | $246.38M | $232.19M |
| Effect of Exchange Rate Changes | -$1.60M | -$1.10M | -$1.49M | $18.02M | $1.61M |
| Free Cash Flow | $85.73M | $10.50M | -$5.05M | -$45.25M | -$19.60M |
| Net Intangibles Purchase and Sale | – | – | – | -$14.20M | – |
| Net Business Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on IART.
Sign in to join the discussion.